logo
UK businesses race to embed AI into enterprise workflows, EXL study finds

UK businesses race to embed AI into enterprise workflows, EXL study finds

Yahoo28-05-2025

Three-quarters of companies believe they have an edge on their competition, but many worry siloed data and talent shortages could impede their AI progress
LONDON, May 28, 2025 (GLOBE NEWSWIRE) -- Businesses in the UK are making significant changes in the ways they work as they increasingly embed AI throughout their workflows and to scale and maximise ROI, according to new research by EXL [NASDAQ: EXLS], a global data and AI company. An 86% majority of organisations have significantly changed their operating model to accommodate AI, with 39% having completely redesigned how they work. Over the next year, companies expect half (50%) of their processes will include AI.
The second annual EXL Enterprise AI Study: Driving Execution at Scale (UK Report) is based on a survey of 190 UK-based C-suite and other senior decision makers across the banking and finance, insurance, retail, utilities, and healthcare payer industries. Its findings shine a spotlight on the massive growth of enterprise GenAI implementations to date but also warn of data quality issues, talent shortages, and other roadblocks that could curtail some of the early progress companies have made as they move deeper into company-wide enterprise AI initiatives.
The following are some of the report's key findings:
Finance Leading the Charge: Leaders have emerged in the AI space, and the survey defines these organisations as those that have developed AI capabilities in at least five of the seven common business functions analysed in the report. Leaders were most likely to come from the banking and finance sector (18%), followed by utilities (16%), insurance (12%), and retail (10%).
Transforming to Enable AI in the Workflow: Organisations are developing new operating models to accommodate AI usage across their enterprise workflows. Overall, 86% of UK corporations have either made significant changes to their operating models (47%) or completely redesigned enterprise-wide operating models (39%) to integrate AI throughout their organisations.
Barriers Still Persist: Despite an average of £23.2 million per company in AI investment, barriers to adoption persist. The largest of these are cost or budget constraints, followed by concerns about data privacy and security, and the lack of a clear AI strategy or vision. What's more, nearly 70% of companies say they have yet to achieve the data accessibility, efficiency, quality, consistency, and transparency required for AI to thrive in their organisations.
Companies Eye the Best Ways to Scale AI: Overall, 88% of respondents said it's very or extremely important for their organization to scale their AI initiatives in the coming year. Executives ranked implementing AI governance (42%) and improving data quality and accessibility (42%) as their top priorities.
Retailers Eager to Make Larger Investments: Retailers are the most likely (42%) to say they are ramping up GenAI significantly, followed by utilities (30%), banking and finance (24%), and insurers (9%).
'The only way large corporations can truly capitalise on the full power of AI is by integrating the technology into enterprise workflows,' said Anand 'Andy' Logani, chief data and AI officer at EXL. 'Executed well, the right AI strategy has the ability to deliver unmatched business value without disrupting core business functions.'
The full report, 2025 EXL Enterprise AI Study: Driving AI Execution at Scale (UK Report), can be accessed here.
About EXL
EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL harnesses the power of data, AI, and deep industry knowledge to transform businesses, including the world's leading corporations in industries including insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 60,000 employees spanning six continents. For more information, visit www.exlservice.com.
ContactsMedia Keith Little+1 703-598-0980 media.relations@exlservice.com
Investor RelationsJohn Kristoff+1 212 209 4613IR@exlservice.com
A PDF accompanying this announcement is available at http://ml.globenewswire.com/Resource/Download/516492ff-fe8c-4563-a2d3-10486840830b

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Meridianbet Seals Sponsorship Deal with Aquatic Sports Association of Malta (ASA)
Meridianbet Seals Sponsorship Deal with Aquatic Sports Association of Malta (ASA)

Yahoo

time5 minutes ago

  • Yahoo

Meridianbet Seals Sponsorship Deal with Aquatic Sports Association of Malta (ASA)

Two-year agreement expands Meridianbet and Golden Matrix's (GMGI) sports sponsorship portfolio across regulated European markets Aquatic Sports Association of Malta VALLETTA, Malta, June 04, 2025 (GLOBE NEWSWIRE) -- Meridianbet, the sports betting and iGaming division of Golden Matrix Group Inc. (NASDAQ: GMGI), a leading developer and licensor of B2B and B2C gaming platforms, today announced the signing of a two-year exclusive sponsorship agreement with the Aquatic Sports Association of Malta (ASA), the official governing body for water polo, swimming, and artistic swimming in Malta. Under the terms of the agreement, Meridianbet becomes the exclusive betting partner of ASA, gaining integrated brand exposure across ASA events, digital platforms, and physical venues. The sponsorship includes the launch of the branded national cup competition - Meridianbet Super Cup, as well as LED road signage, scoreboard branding, and apparel sponsorships across Malta's aquatic sports federations. 'Water polo and aquatic sports are a vital part of Malta's sporting culture,' said Stefan Pavlovic, Malta territory director at Meridianbet. 'This partnership reflects our continued commitment to supporting national sports ecosystems, building long-term brand visibility in regulated markets, and delivering value to fans, players, local institutions and shareholders.' The ASA partnership builds on Meridianbet's growing sponsorship portfolio across 25+ international jurisdictions, where it supports sports ranging from football, basketball and MMA to eSports and grassroots competitions. This announcement also aligns with Meridianbet's broader ESG strategy. In 2024 alone, the company conducted 293 community engagement initiatives, reaching over 18,000 direct and indirect beneficiaries through education, healthcare, sports, and advocacy programs. Key Highlights of the Deal: Meridianbet named exclusive betting partner of Malta's ASA (governing body for water polo, swimming, artistic swimming) Launch of the Meridianbet Super Cup Brand exposure via LED ads, digital platforms, and team apparel To learn more about Meridianbet's community impact programs, visit About Meridianbet Founded in 2001, Meridianbet Group is a well-established online sports betting and gaming group, licensed and currently operating in 18 jurisdictions across Europe, Africa, and South America. The Meridianbet Group's successful business model utilizes proprietary technology and scalable systems, allowing it to operate in multiple countries and currencies with an omni-channel approach to markets, including retail, desktop online, and mobile. The Company is part of the Golden Matrix Group (Nasdaq: GMGI). For more information, visit IR Presentation - YouTube - Twitter - Email: ir@ A photo accompanying this announcement is available at

Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial

Yahoo

time5 minutes ago

  • Yahoo

Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial

Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store